1
Bergey James, Rose Martin: Purgative composition and uses thereof. Inkine Pharmaceutical Company, Bergey James, Rose Martin, COLE Carol, November 9, 2006: WO/2006/118562 (7 worldwide citation)

A purgative composition containing a purgative effective amount of a halogenated carbohydrate is disclosed.


2
Taffy Williams, George Tuszynski, Paul Actor: Retroinverso polypeptides that mimic or inhibit thrombospondin activity. Inkine Pharmaceutical Company, Finnegan Henderson Farabow Garrett & Dunner L, January 15, 2002: US06339062 (6 worldwide citation)

The present invention relates generally to polypeptides that mimic or inhibit the biological activity of thrombospondin, and particularly to polypeptides in retroinverso form. These polypeptides may be used for their biological and pharmaceutical applications such as: (a) inhibiting the invasive and ...


3
Skiendzielewski Stephen, Rose Martin, Do Ngoc: Colonic purgative composition with soluble binding agent. Inkine Pharmaceutical Company, Skiendzielewski Stephen, Rose Martin, Do Ngoc, GARRETT Arthur S, June 9, 2005: WO/2005/051361 (4 worldwide citation)

This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. T ...


4
Taffy Williams, George Tuszynski, Paul Actor: Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions. Inkine Pharmaceutical Company, Philadelphia Health and Education Corporation, Finnegan Henderson Farabow Garrett & Dunner L, April 30, 2002: US06380161 (3 worldwide citation)

The present invention provides methods and compositions for treating cancer and chemotherapy-resistant cancers comprising a chemotherapeutic agent conjugated to or coadministered with a peptide.


5
SKIENDZIELEWSKI STEPHEN, ROSE MARTIN, DO NGOC: Colonic purgative composition with soluble binding agent, Kolon-Abführzusammensetzung mit löslichem Bindemittel, Composition purgative pour le colon a agent de liaison soluble. INKINE PHARMACEUTICAL COMPANY, April 13, 2011: EP2308476-A1

This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. T ...


6
Jacob Leonard S, Williams Taffy J, Krell Robert D: Non-aqueous colonic purgative formulations. Inkine Pharmaceutical Company, August 11, 1999: EP0934071-A1

Orally administered colonic purgative formulations and methods of their use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg3(PO4)2, MgHPO4, Mg(H2PO4)2, MgSO4, MgCl2 ...


7
Jacob Leonard S, Williams Taffy J, Krell Robert D: Formulations purgatives du colon non aqueuses, Non-aqueous colonic purgative formulations. Inkine Pharmaceutical Company, Salix Pharmaceuticals, SMART & BIGGAR, October 8, 1998: CA2256896

Orally administered colonic purgative formulations and methods of their use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg3(PO4)2, MgHPO4, Mg(H2PO4)2, MgSO4, MgCl2 ...


8
SKIENDZIELEWSKI STEPHEN, ROSE MARTIN, DO NGOC: COMPOSITION PURGATIVE POUR LE COLON A AGENT DE LIAISON SOLUBLE, COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT. INKINE PHARMACEUTICAL COMPANY, SALIX PHARMACEUTICALS, SMART & BIGGAR, June 18, 2013: CA2546637

This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. T ...


9
Skiendzielewski Stephen, Rose Martin, Do Ngoc: Colonic purgative composition with soluble binding agent. Inkine Pharmaceutical Company, July 26, 2006: EP1682098-A1

This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. T ...


10
Tuszynski George, Williams Taffy J: Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor. Inkine Pharmaceutical Company, Philadelphia Health &Amp, Educatio, Tuszynski George, Williams Taffy J, June 27, 2001: EP1109900-A1

The present invention provides the sequence of a cell matrix receptor specific for the Cys-Ser-Val-Thr-Cys-Gly (SEQ ID NO:1) region of thrombospondin. Also provided are purification, cloning and expression methods. The receptor protein is useful in numerous diagnostic, prophylactic and therapeutic a ...



Click the thumbnails below to visualize the patent trend.